May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2 years-prospective study
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s40893-017-0027-1
Published Online: 2017-07-10
Published Print: 2017-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
D’Amico, E.
Zanghì, A.
Signori, A.
Grimaldi, LME
Patti, F.